UNC Center for AIDS Research

It's about a real-life response to AIDS - a fierce commitment to creating and translating knowledge that advances the fight against HIV & AIDS

Acknowledge the CFAR Request A Service
  • About
    • Center Overview
    • Resources
      • HIV Matters Podcast Series
      • Training Tools
      • Related Organizations & Websites
    • Acknowledge the CFAR
    • Contact Us
  • Cores & Services
    • Administrative
      • CFAR Office of Community Engagement (OCE)
    • Biostatistics
    • Clinical
    • Clinical Pharmacology/Analytical Chemistry
    • Developmental
    • HIV/STD Laboratory (formerly VIM)
    • International
    • Social & Behavioral Science
  • Working Groups
  • Membership
  • News & Events
    • CFAR News & Announcements
    • CFAR Newsletters
    • Events Calendar
    • Friday Morning Conference
    • CFAR-Wide Webinar Series
    • 2019 Scientific Symposium
    • 2019 NCCC Community Symposium

Promising COVID-19 drug is part of global study being led by UNC researchers

November 16, 2020

Rise Above COVID is a movement to find medicines for COVID-19 through the ACTIV-2 Study, a study for people who have tested positive for COVID-19 in the last 6 days. David Wohl, MD, is vice-chair of ACTIV-2, which is sponsored by the NIH with UNC CFAR researchers Joseph Eron, MD, and William Fischer, MD, as co-investigators. CFAR investigators are deeply involved in UNC’s COVID-19 response. 

The U.S. Food and Drug Administration recently authorized the emergency use of bamlanivimab, a monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19.

“Bamlanivimab is one of the drugs that Wohl and a team of researchers are studying through the ACTIV-2 clinical trial. The trial is enrolling at over 60 U.S. sites and will soon expand globally, including Brazil, Peru, and South Africa. Begun in September, ACTIV-2 is now studying 300 participants, including 30 at UNC. Throughout the long-running study, investigators will add and remove promising treatments as they become available. The goal is to develop a treatment that prevents the virus from developing into a severe illness requiring hospitalization.

This story first appeared November 16, 2020 on the UNC Institute for Global Health and Infectious Diseases website.

News

Recent Posts

  • NICHD Grant Award Enables Researchers To Address Reasons For Vertical Transmission of HIV in Malawi As the Country Pursues Elimination Goals: Integrated Educational Cores Represent the Best of Capacity Building with Malawian Health Leaders
  • Gut Microbiome Can Increase Risk, Severity of HIV, EBV Disease
  • UNC CFAR Biostatistics Core Director, Michael Hudgens appointed to lead Gillings School’s Department of Biostatistics
  • UNC CFAR’s HIV/STD Core Associate Director, De Paris Receives Grant to Study HIV Vaccination in Infant Disease Models
  • Highlights from the 2023 HPTN Annual Meeting

GET IN TOUCH

UNC Center for AIDS Research
Lineberger Cancer Center
Chapel Hill, NC 27599
Email: prema_menezes@med.unc.edu

Follow Us

CFAR User Login
small_blue_trans
© 2018-2023 UNC CFAR. All rights reserved. Website by AndiSites Inc.